Wall Street brokerages expect PerkinElmer, Inc. (NYSE:PKI) to report sales of $722.53 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for PerkinElmer’s earnings, with the lowest sales estimate coming in at $720.00 million and the highest estimate coming in at $724.08 million. PerkinElmer posted sales of $674.31 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.2%. The company is scheduled to announce its next quarterly earnings results on Wednesday, October 30th.
On average, analysts expect that PerkinElmer will report full-year sales of $2.91 billion for the current fiscal year, with estimates ranging from $2.90 billion to $2.93 billion. For the next financial year, analysts anticipate that the firm will report sales of $3.11 billion, with estimates ranging from $3.06 billion to $3.15 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for PerkinElmer.
PerkinElmer (NYSE:PKI) last posted its earnings results on Monday, July 29th. The medical research company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.01). The firm had revenue of $722.50 million for the quarter, compared to the consensus estimate of $729.10 million. PerkinElmer had a net margin of 9.01% and a return on equity of 16.07%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.91 earnings per share.
Shares of NYSE PKI traded up $0.04 during midday trading on Thursday, reaching $86.10. 415,873 shares of the stock traded hands, compared to its average volume of 715,974. The stock has a market capitalization of $9.58 billion, a PE ratio of 23.85, a P/E/G ratio of 1.53 and a beta of 1.29. The company’s 50 day moving average is $83.25 and its 200 day moving average is $91.18. PerkinElmer has a one year low of $71.83 and a one year high of $103.00. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.89 and a quick ratio of 1.31.
The business also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be given a $0.07 dividend. The ex-dividend date is Thursday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.33%. PerkinElmer’s dividend payout ratio is presently 7.76%.
In other PerkinElmer news, Director Alexis P. Michas sold 2,000 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $82.56, for a total value of $165,120.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.80% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. Crawford Investment Counsel Inc. increased its stake in PerkinElmer by 1.1% in the first quarter. Crawford Investment Counsel Inc. now owns 9,860 shares of the medical research company’s stock worth $950,000 after purchasing an additional 110 shares during the period. Mason Street Advisors LLC increased its stake in shares of PerkinElmer by 0.8% during the first quarter. Mason Street Advisors LLC now owns 15,807 shares of the medical research company’s stock valued at $1,523,000 after buying an additional 124 shares during the period. Retirement Systems of Alabama increased its stake in shares of PerkinElmer by 0.3% during the second quarter. Retirement Systems of Alabama now owns 51,726 shares of the medical research company’s stock valued at $4,983,000 after buying an additional 134 shares during the period. Securian Asset Management Inc increased its stake in shares of PerkinElmer by 1.2% during the second quarter. Securian Asset Management Inc now owns 11,504 shares of the medical research company’s stock valued at $1,108,000 after buying an additional 141 shares during the period. Finally, Glen Harbor Capital Management LLC increased its stake in shares of PerkinElmer by 3.9% during the second quarter. Glen Harbor Capital Management LLC now owns 3,840 shares of the medical research company’s stock valued at $370,000 after buying an additional 144 shares during the period. Institutional investors and hedge funds own 95.20% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Article: What is Net Asset Value (NAV)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.